These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 1477641

  • 1. Clinical use of recombinant plasminogen activator for intraocular fibrinolysis.
    Koerner F, Boehnke M.
    Ger J Ophthalmol; 1992; 1(5):354-60. PubMed ID: 1477641
    [Abstract] [Full Text] [Related]

  • 2. [Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy].
    Zhao P, Wang W.
    Zhonghua Yan Ke Za Zhi; 1995 Jul; 31(4):255-8. PubMed ID: 8745515
    [Abstract] [Full Text] [Related]

  • 3. Tissue plasminogen activator for the treatment of postoperative intraocular fibrinous membranes following cataract surgery.
    Schmitz K, Greite JH, Bartenschlager EM.
    Ger J Ophthalmol; 1995 Mar; 4(2):75-9. PubMed ID: 7795512
    [Abstract] [Full Text] [Related]

  • 4. [Acute band-shaped keratopathy after intraocular fibrinolysis with recombinant tissue plasminogen activator (rt-PA)].
    Althaus C, Schelle C, Sundmacher R.
    Klin Monbl Augenheilkd; 1996 Nov; 209(5):318-21. PubMed ID: 9044983
    [Abstract] [Full Text] [Related]

  • 5. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

  • 6. [Treatment of intraocular fibrinous membrane by anterior chamber injection of tissue plasminogen activator after IOL implantation].
    Xie L, Li S, Dong X, Cao J, Shi W, Guo P.
    Zhonghua Yan Ke Za Zhi; 1998 Jul 02; 34(4):291-3. PubMed ID: 11877211
    [Abstract] [Full Text] [Related]

  • 7. [Tissue plasminogen activator in treatment of fibrinous membranes after cataract surgery].
    Oficjalska-Młyńczak J, Marek J, Zajac-Pytrus H, Nizankowska MH, Koziorowska M.
    Klin Oczna; 1996 Jul 02; 98(6):423-5. PubMed ID: 9340414
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical use of recombinant tissue plasminogen activator for anterior chamber fibrinolysis.
    Lin CP.
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1994 Jun 02; 10(6):332-6. PubMed ID: 8057416
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of intracameral fibrinous membranes with tissue plasminogen activator.
    Erol N, Ozer A, Topbas S, Yildirim N, Yurdakul S.
    Ophthalmic Surg Lasers Imaging; 2003 Jun 02; 34(6):451-6. PubMed ID: 14620747
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tissue plasminogen activator and penetrating keratoplasty.
    Heidemann DG, Williams GA, Blumenkranz MS.
    Ophthalmic Surg; 1990 May 02; 21(5):364-5. PubMed ID: 2116614
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator.
    Williams GA, Lambrou FH, Jaffe GA, Snyder RW, Green GD, Devenyi RG, Abrams GW.
    Arch Ophthalmol; 1988 Aug 02; 106(8):1055-8. PubMed ID: 3135790
    [Abstract] [Full Text] [Related]

  • 17. Tissue plasminogen activator for postvitrectomy fibrin formation.
    Jaffe GJ, Abrams GW, Williams GA, Han DP.
    Ophthalmology; 1990 Feb 02; 97(2):184-9. PubMed ID: 2109297
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Sonothrombolysis for intraocular fibrin formation in an animal model.
    Yamashita T, Ohtsuka H, Arimura N, Sonoda S, Kato C, Ushimaru K, Hara N, Tachibana K, Sakamoto T.
    Ultrasound Med Biol; 2009 Nov 02; 35(11):1845-53. PubMed ID: 19699025
    [Abstract] [Full Text] [Related]

  • 20. Tissue plasminogen activator as a biochemical adjuvant in vitrectomy for proliferative diabetic vitreoretinopathy.
    Hesse L, Chofflet J, Kroll P.
    Ger J Ophthalmol; 1995 Nov 02; 4(6):323-7. PubMed ID: 8751095
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.